European Journal of Haematology
Treatment Patterns, Outcomes and Survival Trends in T‐Cell Prolymphocytic Leukemia: A Nationwide Population‐Based Study in the Netherlands
ABSTRACT Background T‐cell prolymphocytic leukemia (T‐PLL) is a rare, aggressive mature T‐cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population‐level outcomes remain poorly defined. Methods All T‐PLL cases diagnosed between 2001 and 2023 were identified from the nationwide Netherlands Cancer Registry. Overall survival (OS) and survival after relapse (OS2) …